DMTK - DMTK STOCK NEWS: Shareholders With Large Losses Should Contact Robbins LLP for Information About Their Rights Against DermTech Inc. | Benzinga
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired DermTech, Inc. (NASDAQ:DMTK) securities between May 3, 2022 and November 3, 2022. DermTech is a molecular diagnostic company that develops and markets non-invasive genomics tests to aid the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions.
For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What is this Case About: DermTech, Inc. (DMTK) Misled Investors Regarding its Business Prospects
According to the complaint, on August 8, 2022, DermTech announced its second quarter 2022 financial results and revealed that the Company expected "a lower average selling price (ASP) for [its] DMT," due to "Medicare billing code edits . . . as well as less favorable collection patterns from commercial payors." On this news, the Company's stock price fell $2.87, or 34%, to close at $5.56 per share on August 9, 2022.
Then, on ...